老年弥漫大B细胞淋巴瘤患者“R+化疗”预后相关因素分析  

The Factors Associated with the Prognosis of Rituximab and Chemotherapy in Elderly Patients with Diffuse Large B-Cell Lymphoma

作　　者：林方珩 LIN Fangheng(Department of Hematology,Quanzhou First Hospital,Fujian Medical University,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属泉州第一医院血液内科,泉州362000

出　　处：《中国医药指南》2024年第2期85-87,共3页Guide of China Medicine

摘　　要：目的分析老年弥漫大B细胞性淋巴瘤(DLBCL)患者行“R+化疗”治疗6周期后临床效果的相关因素。方法该回顾性分析纳入我院2019年1月至2022年1月收治的118例老年DLBCL患者的临床资料,通过单因素和多因素逻辑回归分析与6周期“R+化疗”治疗预后相关的血液学指标。结果外周血淋巴细胞计数/单核细胞计数(LMR)下降、EB病毒感染、血β_(2)微球蛋白升高是老年DLBCL患者6周期“R+化疗”后良好预后的独立危险因素。结论LMR、EB病毒感染、血β2微球蛋白水平与老年DLBCL患者“R+化疗”治疗效果相关。Objective To analyze the factors related to the clinical outcome of elderly patients with diffuse large B-cell lymphoma(DLBCL)after 6 cycles of Rituximab(R)+chemotherapy.Methods The retrospective analysis included the clinical data of 118 elderly DLBCL patients admitted to our hospital from January 2019 to January 2022,and the hematological indexes related to the prognosis of 6 cycles of R+chemotherapy were analyzed by unifactorial and multifactorial logistic regression.Results Decreased LMR,EBV infection,and elevated bloodβ_(2)-microglobulin were independent risk factors for good prognosis of elderly DLBCL patients after 6 cycles of R+chemotherapy.Conclusions LMR,EB virus infection,and bloodβ2-microglobulin levels were associated with the outcome of R+chemotherapy in elderly DLBCL patients.

关 键 词：老年 弥漫大B细胞性淋巴瘤 “R+化疗”治疗 EB病毒 

分 类 号：R733.4[医药卫生—肿瘤]